
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated a consistent upward trend in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units, suggesting growing demand for its myoelectric orthosis products. The company's strategic focus on the large Medicare market is expected to redirect growth, with orthotics and prosthetics providers contributing approximately 22% of revenue in 2024. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services to include the MyoPro in Medicare Part B benefits significantly expands the potential market for Myomo, enhancing its growth prospects.
Bears say
Myomo Inc. has lowered its revenue guidance for 2025 to $40-42 million from a previous estimate of $50-53 million, indicating a significant decline in expected performance. Additionally, the company has reported a decrease in its backlog of insurance-authorized sales, which fell to 208 from 230 in the previous quarter, suggesting weakening demand for its products. Furthermore, the company's marketing strategies and pipeline quality have not met expectations, adversely affecting lead conversion rates and further contributing to a negative outlook for future revenue performance.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares